Drug
Domvanalimab clinical trials
Also written AB154 and GS-0154.
- studies test it
- 20
- open now
- 1
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the domvanalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 3 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 16
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 10
Gilead Sciences (5) · Arcus Biosciences, Inc. (4) · Hospices Civils de Lyon (2) · Fundación para el Progreso de la Oncología en Cantabria (1) · AstraZeneca (1) · University of Texas Southwestern Medical Center (1) · Washington University School of Medicine (1) · Yale University (1)
Often tested with
Tested in the same studies.
Zimberelimab (15) · Sacituzumab govitecan (4) · AB928 (3) · Quemliclustat (2) · Carboplatin (2) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1)
Studies
Open first, then newest update. How each study uses domvanalimab is read from its arms, and is right about nine times in ten.
Testing it · 20
- Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Not yet recruitingPhase 2Hospices Civils de LyonNCT07337447Written as FOLFIRI + Zimberelimab + Domvanalimab
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerCompletedPhase 2Arcus Biosciences, Inc.NCT04736173Written as Domvanalimab
- PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerActive, not recruitingPhase 2Fundación para el Progreso de la Oncología en CantabriaNCT06133517Written as Domvanalimab
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesActive, not recruitingPhase 2Arcus Biosciences, Inc.NCT05329766Written as Domvanalimab
- Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Active, not recruitingPhase 2Gilead SciencesNCT06727565Written as Domvanalimab
- A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyCompletedPhase 3Arcus Biosciences, Inc.NCT05568095Written as Domvanalimab
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingPhase 2Gilead SciencesNCT03547973Written as Domvanalimab
- A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCActive, not recruitingPhase 3AstraZenecaNCT05211895Written as Domvanalimab
- Domvanalimab and Zimberelimab in Advanced Liver CancersActive, not recruitingPhase 2University of Texas Southwestern Medical CenterNCT05724563Written as Domvanalimab
- IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingPhase 2Hospices Civils de LyonNCT06790706Written as DOMVANALIMAB + ZIMBERELIMAB
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerCompletedPhase 2Arcus Biosciences, Inc.NCT04262856Written as Domvanalimab
- Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerActive, not recruitingPhase 2Washington University School of MedicineNCT04791839Written as Domvanalimab
- Switch Maintenance in PancreaticSuspendedPhase 1/2James Cleary, MD, PhDNCT05419479Written as DOMVANALIMAB
- Study With Various Immunotherapy Treatments in Participants With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05676931Written as Domvanalimab
- Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05633667Written as Domvanalimab (DOM)
- Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWithdrawnPhase 2MedSIRNCT07134556Written as Domvanalimab (DOM)
- AB154 Combined With AB122 for Recurrent GlioblastomaActive, not recruitingEarly Phase 1Yale UniversityNCT04656535Written as Domvanalimab
- Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory MelanomaActive, not recruitingPhase 2Diwakar DavarNCT05130177Written as Domvanalimab
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Gilead SciencesNCT05502237Written as Domvanalimab
- Zimberelimab + Domvanalimab in Gastroesophageal AdenocarcinomaWithdrawnPhase 2Massachusetts General HospitalNCT07283848Written as Domvanalimab
Given in every arm · 2 — domvanalimab is usual care beside what is tested
Codes
What other systems call domvanalimab · ClinicalTrials.gg INT014805
- UNII (FDA) 45X7OU8C4JDOMVANALIMABOne source FDA
- NCI Thesaurus C162875DomvanalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 45X7OU8C4J | DOMVANALIMAB | One source FDA |
| NCI Thesaurus | C162875 | Domvanalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.